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ABSTRACT
Antithymocyte globulins (ATG) are purified, concentrated preparations of polyclonal immunoglobulin G from
hyperimmune serum of horses or rabbits immunized with human thymus lymphocytes. Both the horse and the
rabbit products induce immunosuppression as a result of lymphocyte depletion and immune modulation. The
exact mechanism of action is unknown but may include T-cell clearance from the circulation and modulation
of T-cell activation, homing, and cytotoxic activities. Both horse and rabbit ATG include multiple antibodies
against T-cell surface antigens and have been used extensively in allogeneic hematopoietic progenitor cell
transplantation (HPCT) for the treatment and prevention of graft-versus-host disease or graft rejection. To
quantify the active ATG after HPCT, we developed a flow-based assay to measure residual ATG capable of
binding to lymphocytes. In contrast to prior assays that measure total rabbit or horse immunoglobulin, this
assay quantitates only the antibody capable of binding to lymphocytes, which presumably reflects the func-
tionally active fraction of the xenoantiserum. Thirty patients with hematologic malignancies underwent T
cell–depleted HPCT and had ATG levels assayed during the peritransplantation period. The time required for
ATG levels to decay to background was quite variable (mean, 46 days; range, 14-91 days), although most
patients demonstrated a rapid early clearance followed by a slower decline. The actual mean half-life was 6.8
days (range, 2.4-14.0 days). The persistence of ATG for months after administration has significant implica-
tions for the pace of immune reconstitution after transplantation and is a potentially confounding variable in
any study that involves early administration of donor lymphocyte infusions or other cellular transfer. These
findings indicate that ATG levels should be explicitly measured in studies that involve early donor lymphocyte
administration so that proper conclusions regarding dose, safety, and efficacy can be reached.
© 2005 American Society for Blood and Marrow Transplantation
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GNTRODUCTION
Antithymocyte globulins (ATG) are widely used in
olid organ transplantation in humans to treat or prevent
cute cellular rejection of allograft kidneys or livers, as
ell as in hematopoietic progenitor cell transplantation
HPCT) to prevent or treat graft-versus-host disease
GVHD) [1,2]. ATG preparations are puriﬁed con-
entrated immunoglobulin G from hyperimmune se-
um of horses or rabbits immunized against human [
B&MThymus lymphocytes. They contain cytotoxic antibod-
es directed against antigens expressed on human T
ymphocytes, including CD2, CD3, CD4, CD8,
D11a, CD18, CD25, CD44, CD45, HLA-DR,
LA class I heavy chains, and 2-microglobulin. Both
orse and rabbit products induce immunosuppression
3,4] as a result of lymphocyte depletion and immune
odulation and thereby reduce the incidence of
VHD [5-8] and the rate of graft failure in HPCT9-11]. We have studied the pharmacokinetics of ac-
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6ive ATG, which we deﬁne as the subset of antibodies
ithin the ATG preparation that are capable of bind-
ng to human lymphocytes, in 30 consecutive adult
atients (aged 18-65 years) who received transplants
rom matched or partially mismatched donors and
ho underwent CD34-selected HPCT. We have de-
eloped a 2-color ﬂow-based assay to determine the
mount of detectable circulating ATG in the body
hat is capable of binding to speciﬁc leukocyte subsets,
uch as CD3 T cells. In an effort to boost immune
econstitution, it has become our institutional stan-
ard to provide donor lymphocyte infusions (DLI) as
oon as possible after T cell–depleted/CD34-selected
PCT. However, the effectiveness of DLI may be
ompromised if high levels of ATG remain in the
irculation. Thus, the ability to determine the level of
esidual ATG capable of binding to speciﬁc lympho-
yte subsets provides valuable information to optimize
doptive immunotherapy for these patients. Our re-
ults demonstrate that ATG clearance is variable and
hat levels must be individually monitored if the goal
s to administer DLI early in the posttransplantation
eriod.
ATERIALS AND METHODS
ligibility
Between March 1999 and June 2004, all patients
ho were eligible to receive a T cell–depleted (CD34-
nriched) HPCT were offered participation in a study
f an all-chemotherapy conditioning regimen in com-
ination with ATG. Patients were eligible if they had
n Eastern Cooperative Oncology Group performance
tatus of 0 or 1, normal or nearly normal cardiac,
ulmonary, hepatic, and renal function, and a hema-
ologic malignancy appropriate for transplantation.
atients with matched sibling donors, well-matched
nrelated donors, and haploidentical donors were el-
gible. The study was approved by the Thomas Jeffer-
on University Institutional Review Board, and in-
ormed consent was obtained for all participating
atients.
onditioning Regimen and Supportive Care
All patients received a preparative regimen of ﬂu-
arabine, cytarabine, and melphalan, followed by a
D34-selected HPCT. The ﬁrst 14 patients pre-
ented here received rabbit ATG (Thymoglobulin;
enzyme, Cambridge, Massachusetts) at a total dose
f 20 mg/kg during the peritransplantation period.
he subsequent 16 patients received a total dose of 16
g/kg. ATG was administered at a dose of 4 mg/kg
n days 3, 2, 2, and 4 and in the initial 14
atients on day 6 as well. Prophylactic antibiotics
onsisted of an amphotericin product, valacyclovir,
nd trimethoprim-sulfamethoxazole in all patients. All m
10atients received transfusion support with leukode-
leted and irradiated cellular blood products. Patients
ho were cytomegalovirus (CMV) seronegative re-
eived CMV-seronegative blood products.
TG Levels
Patients had blood drawn for ATG levels before
TG administration, on the day of transplantation, on
ay 7 after HPCT, and generally weekly thereafter.
eripheral blood mononuclear cells were prepared by
icoll-Hypaque density gradient centrifugation. To
repare a standard curve for comparison purposes,
TG was initially diluted in normal serum to a con-
entration of 20 g/mL. This ATG solution was, in
urn, serially 2-fold diluted with normal human serum
o produce a series of ATG standards ranging from 20
o 0.078 g/mL. Normal donor cells (100 L) were
dded to 20 L of either patient serum or ATG
tandards to achieve a ﬁnal concentration of 0.5 to
.0  106 cells per tube. Patient serum was run neat
nd diluted 1:1 with normal donor serum in each
ssay. After a 30-minute incubation and 3 washes, the
ormal donor cells, now coated with ATG, were la-
eled with goat anti-rabbit ﬂuorescein isothiocyanate
FITC) and, in some cases, with phycoerythrin-con-
ugated anti-CD3 (CD3 PE). Flow cytometric analysis
as performed with a FACScan (Becton Dickinson,
inger Lakes, NJ).
After the ﬂow cytometric analysis, a titration curve
as developed by plotting the ATG level (micrograms
er milliliter) from the ATG standards (y-axis) versus
he geometric mean log ﬂuorescence intensity (x-axis).
he equation of the regression line of this plot was
sed to calculate patient ATG levels by using the
quation y  ax  b, where a is the slope of the
egression line and b is the y-intercept.
harmacokinetic Analysis
Pharmacokinetic analysis was performed with Win-
onlin Professional 4.1 (Pharsight, Mountain View,
A). Given the known biexponential decline of rabbit
TG [8], data were ﬁt to a 2-compartment model with
ubsequent generation of secondary pharmacokinetic
arameters. For patients with fewer data points, data
ere ﬁt to a monoexponential model. Goodness of ﬁt
as assessed by examination of graphical representa-
ions of residuals, condition number, and Akaike in-
ormation criteria [12].
ESULTS
atients
Thirty patients with hematologic malignancies
acute lymphoblastic leukemia, n  10; acute myelog-
nous leukemia, n  14; chronic myelogenous leuke-
ia, n  4; non-Hodgkin lymphoma, n  1; and
Table 1. Patient Characteristics
Patient
No.
Age
(y) Sex
Disease—Disease Status
at Transplantation Donor
ATG Dose
(mg/kg)
CD34 Dose/kg
(106)
CD3 Dose/kg
(104)
Hematologic Recovery
Opportunistic Infections
ANC >500 (Day after
HPCT) (106/L)
PLT >20000 (Day after
HPCT) (106/L)
1 60 M AML-PIF Haplo-son 20 7.49 1.78 12 23
2 33 F ALL-1st CR High risk-
karyotype
Haplo-M 20 1.98 4.82 13 NA
3 54 F ALL-refractory (therapy
related)
Haplo-sib 20 4.53 2.32 13 NA HSV
4 18 F ALL-1st CR High risk Sib 20 13.8 5.00 12 19
5 59 M AML-1st CR High-risk
karyotype
mURD 20 1.22 1.85 13 NA CMV rising PCR titer
6 65 M ALL-1st CR High risk Sib 20 2.08 0.88 10 28
7 19 M ALL-2nd CR mURD 20 3.14 2.13 15 32 MAI
8 34 F AML-PIF Haplo-sib 20 4.36 4.94 12 30 CMV pneumonia
9 49 M AML-PIF Sib 20 3.52 3.75 12 17
10 19 M AML-PIF Sib 20 6.35 5.00 13 17
11 32 M NHL-refractory Haplo-M 20 4.43 1.45 11 NA
12 56 M CMML/AML Sib 20 3.15 3.40 10 57
13 22 M CML (LBP-1st CR) Sib 20 5.63 3.37 13 19 Adenovirus
14 35 M ALL-1st relapse Haplo-F 20 2.20 0.99 13 22
15 38 M ALL-1st relapse Haplo-M 16 5.16 2.72 38 NA
16 53 M CML-Acc phase Sib 16 3.75 1.04 10 NA CMV rising PCR titer
17 52 F AML-1st CR Sib 16 4.73 2.72 10 24
18 60 F ALL-1st CR mmURD 16 1.78 7.76 14 NA
19 61 M ALL-1st CR Sib 16 5.53 1.50 10 NA CMV rising PCR titer
20 52 M AML-1st relapse mURD 16 3.83 1.45 14 NA VRE blood
21 60 M Myelofibrosis mmURD 16 7.82 2.04 10 NA
22 24 M AML-refractory Haplo-sib 16 2.91 0.30 12 NA Aspergillus, BK hemorrhagic
cystitis, adenovirus
23 59 M AML-1st remission Sib 16 3.83 1.45 19 19
24 56 F CML-Acc phase mURD 16 2.69 19.8* 12 19
25 60 M AML h/o MDS mmURD 16 1.41 2.48 14 NA CMV rising PCR titer
26 28 M AML-1st relapse Sib 16 8.49 4.47 12 19 EBV-PTLD, adenovirus
27 43 M CML-CP Haplo-D 16 4.19 0.97 11 22 CMV rising PCR titer
28 36 F AML-1st relapse Haplo-sib 16 19.8 0.42 11 21 CMV rising PCR titer, oral HSV
29 58 F AML-2nd CR mURD 16 3.32 4.47 14 28 Oral HSV
30 66 M AML-1st CR 2 ag mmURD 16 2.91 0.96 13 NA
The median age was 52 years (range, 18-66 years). Three patients received transplants from unrelated donors with a single antigen mismatch (mmURD), 1 from a 2-antigen–mismatched unrelated donor
(2 ag mmURD), 5 from completely matched (10/10) unrelated donors (mURD), 10 from haplodisparate family donors (3 maternal donors [Haplo-M], 1 paternal donor [Haplo-F], 1 son donor
[Haplo-son], 1 daughter donor [Haplo-D], and 4 sibling donors [Haplo-sib], and 11 from HLA-identical sibling donors (Sib). Patient 24 received a larger CD3 dose (19.8  104/kg) based on a
required CD34 dose of 2  106. This patient also received a total of 20 mg/kg ATG although it had originally been planned that she receive a total of 16 mg/kg. She has not developed GVHD
or any opportunistic infection. White cell and platelet engraftment are shown. All patients had prompt neutrophil recovery, but 12 patients never recovered a sustained platelet count 20000.
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CR, complete remission; NHL, non-Hodgkin lymphoma; CMML, chronic myelomonocytic leukemia; MDS,
myelodysplastic syndrome; CP, chronic phase; NA, not applicable; HSV, herpes simplex virus; PCR, polymerase chain reaction; MAI, Mycobacterium avium-intracellulare; VRE, vancomycin-resistant
enterococcus; EBV-PTLD, Epstein-Barr virus–related posttransplantation lymphoproliferative disorder; ANC, absolute neutrophil count; PLT, platelets; PIF, primary induction failure; LBP,
lymphoid blast phase; Acc, accelerated phase; h/o; history of; BK, BK virus.
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6yeloﬁbrosis, n  1) underwent CD34-enriched
PCT (Table 1). Eleven patients had HLA-identical
ibling donors, 9 had unrelated donors, and 10 had
aplodisparate donors. Although true peak levels (im-
ediately after the last ATG infusion) could not be
btained in all patients, every patient had an initial
TG level measured within 48 hours of the last ATG
nfusion. Twenty-six of 30 patients were evaluable for
etermination as to when levels had decayed to less
han 2.0 g/mL, and 20 were evaluable for determi-
ation as to when levels had decreased to less than 1.0.
atients were no longer evaluable for ATG levels if
hey developed relapse of their underlying malignancy
r died or if, for other reasons, too few samples were
btained for meaningful analysis.
TG Levels
Figure 1 illustrates the typical results observed
hen cells were stained with the ATG standards. As
een in Figure 1A, the peak and mean (or geometric
ean) log ﬂuorescence progressively decline as rabbit
TG concentration is diluted. This reﬂects the fact
hat these ATG concentrations are not saturating.
he resulting regression line (ATG concentration
ersus geometric mean log ﬂuorescence intensity) is
llustrated in Figure 1B. R2 values were greater than
.98 in 90% of the assays, thus demonstrating that the
elationship between these variables was linear. In
eneral, data derived from mean log ﬂuorescence and
eometric mean log ﬂuorescence were identical.
owever, the geometric mean tends to correlate best
ith the peak seen on histograms and is therefore
referred if there is any discrepancy between the 2
alues.
The serum ATG level was determined by com-
aring the mean channel of ﬂuorescence intensity in
atient serum with the mean channel of ﬂuorescence
ntensity of the serially diluted ATG standards. Figure
A shows an overlay of histograms from a sample
atient on days 3 (before ATG), 0 (after 2 doses of
TG),7 (24 hours after the last dose of ATG),14,
21, 28, 47, and 61. Histograms are from un-
iluted patient serum samples. Similar histograms, but
ith values corresponding to a 50% lower ATG level,
ere seen in patient samples that had been diluted 1:1
ith normal serum. Figure 2B shows the gradual loss
f active ATG from the sample patient’s serum over
ime. In this patient, the half-life of ATG was 2.45
ays, and the ﬁrst occurrence of an ATG level less
han 2 g/mL was noted at day 47 after transplanta-
ion. Observed ATG levels declined to less than 2.0
g/mL at a range of 14 to 91 days after HPCT
median, 45.5 days; mean, 46.0 days), thus reﬂecting a
rolonged, but variable, half-life. The observed peak
evels (Figure 3A) of rabbit ATG ranged from 8.07 to
0.74 g/mL (mean, 21.1 g/mL) on day 7 after o
12PCT, within 12 to 72 hours of the ﬁnal ATG dose.
here was no correlation between the magnitude of
he initial level and the time to the disappearance of
TG (Figure 3B).
Originally it had been planned that patients would
eceive DLI once the ATG level declined to less than
.0 g/mL. However, given the available data regard-
ng the mechanism of action of ATG at various blood
evels, it was decided to adjust this to give DLI once
he ATG declined to less than 2.0 g/mL [9]. In
ddition, the time to observed disappearance to a level
ess than 1.0 g/mL was much longer than the time to
level less than 2.0 g/mL. In 9 of 20 evaluable
atients, this delay would have also caused a signiﬁ-
ant delay in the time to planned DLI (data not
hown).
ecline in ATG Antibodies Capable of Binding to
pecific Leukocyte Subpopulations
Our original ATG measurements used a 1-color
ssay that analyzed all lymphocyte subpopulations
n the aggregate. However, some samples demon-
trated 2 populations of ATG coated cells reﬂected
n 2 peaks on the 1-color histogram or a shoulder or
ail on the histogram, as demonstrated in Figure 4A.
sually the larger population was also the brighter
opulation, but this was not always the case. Our
oal was to determine when ATG levels had de-
reased below concentrations that would eliminate
cells or interfere with their function. Therefore,
n an effort to distinguish CD3 cells from the
D3 fraction, the assay was converted to a 2-color
ssay by adding CD3 PE. The assay was subse-
uently performed with other lineage-speciﬁc anti-
odies. Our rationale was that ATG is a polyspeciﬁc
erum containing some antibodies (such as to
D45) that may bind broadly to human leukocytes
nd others (such as CD3) that may be lineage spe-
iﬁc. We assumed that the rapid recovery and turn-
ver of neutrophils after the early recovery of this
ell population would deplete the serum of both
road and lineage-speciﬁc antibodies capable of
inding to neutrophils through absorption to the
eutrophil surface. Natural killer (NK) cells, a pop-
lation with similar rapid recovery, might also ab-
orb these antibodies quickly. In contrast, we antic-
pated that the decline of T cell–speciﬁc antibodies
ould occur more slowly because there would be
ewer cells to absorb these antibodies from the se-
um; therefore, the decay in levels would reﬂect
nly protein catabolism.
Figure 4 shows histograms from a sample patient
or whom both analyses were performed. In the sin-
le-color assay (Figure 4A), there are 2 populations of
ITC cells. It is difﬁcult to determine which popu-
ation is the appropriate one for determining the level
f ATG. However, when the same serum is tested by
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ATG Clearance after HPCT
Bsing the 2-color assay (Figure 4B and C), it becomes
lear that the brighter population is CD3, and the
og ﬂuorescence of this subpopulation is used for a
ore precise determination of the level of residual
TG capable of binding to T cells. Intriguingly, when
igure 1. ATG titration. A, Mean log ﬂuorescence progressively de
TG concentrations are not saturating. B, A sample ATG titration
nd standard dilutions of ATG (y-axis). Mean log ﬂuorescence from
.0251x  0.7147, where y is the mean ﬂuorescence and x is the reTG binding to neutrophils, B cells, NK cells, and T b
B&MTells was separately assessed, the data demonstrated
hat the levels in each case fell in parallel (Figure 5).
iven the early recovery of neutrophils and NK cells
fter transplantation and the slow recovery of T cells
fter transplantation, these data would argue that in
s rabbit ATG concentration is diluted, reﬂecting the fact that these
n, depicting the association between mean log ﬂuorescence (x-axis)
t samples from the same experiment are used in the equation y 
at corresponds to the patient’s ATG level.clines a
is show
patien
sult thoth cases, antibody catabolism—not absorption—is
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6he primary mechanism responsible for the decline in
TG levels in serum.
evelopment of GVHD or Opportunistic Infection
Only 1 patient (3.3%) developed GVHD, but 13
43%) of 30 patients developed a total of 17 opportu-
istic infections, including CMV (n  7), Epstein-
igure 2. ATG disappearance: the gradual loss of ATG from the s
sample patient shows the mean log ﬂuorescence of samples from
ame data with corresponding ATG levels plotted against time afte
y a biexponential model.arr–related posttransplantation lymphoproliferative s
14isease (n  1), herpes simplex (n  3), Mycobacterium
vium-intracellulare (n  1), idiopathic pneumonia
n  2), candida esophagitis (n  1), and adenovirus
n 2) infections. In some cases (for example, increas-
ng CMV viral load by polymerase chain reaction), the
pportunistic infections were treated rapidly and suc-
essfully, but often the opportunistic infections led to
f a sample patient is illustrated. A, An overlay of histograms from
e point, with a gradual decline of ﬂuorescence over time. B, The
T. In most cases, pharmacokinetic parameters were best describederum o
each tim
r HPCigniﬁcant morbidity or mortality.
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ATG Clearance after HPCT
Bharmacokinetics
Pharmacokinetic parameters were determined
or 24 patients. Fourteen of these patients had phar-
acokinetic parameters best described by a biexpo-
ential model. A representative patient tracing is
hown in Figure 2B. Ten patients with sparser data
ets had proﬁles best described by a monoexponen-
ial, 1-compartment model. Six patients were not
valuable because of a lack of sufﬁcient data. Phar-
acokinetic parameters are listed in Table 2. The
verall half-life of ATG was 6.8 days (SD, 2.9 days).
he alpha distributive phase had a half-life of 3.0
ays, and the beta elimination half-life was 17.9
ays. The volume of distribution was 47.2 L (SD,
4.9 L), which approximates total body water. The
igure 3. ATG levels. A, Observed peak ATG levels for all 30
atients. In most patients, this level was obtained on day 7 after
PCT and reﬂects a total of 4 or 5 doses of ATG; the ﬁnal dose was
iven on day 4 or 6. Levels ranged from 8.07 to 40.74 g/mL
median, 21.69 g/mL). Patient identiﬁcation numbers are shown
long the x-axis and indicate that there was no difference between
atients treated earlier in the study (who received a 20 mg/kg ATG
otal dose) and those treated later in the study (who received a 16
g/kg total dose). B, Lack of correlation between observed peak
TG levels and time to disappearance to an ATG level 1 g/mL.
imilarly, there was no correlation between these levels and the
ime to an ATG level 2.5, 2.0, or 1.5 g/mL (data not shown for
ll levels).olume of distribution did not seem to be inﬂu-
B&MTigure 4. Two-color ﬂow assay: by using single-color ﬂow (A), 2
ITC populations of cells can be seen. In this example, the
righter population is the larger one, although in other cases (data
ot shown) it is the smaller population. With the 2-color ﬂow-based
ssay and the addition of CD3 PE (B and C), it becomes clear that
he brighter population is the clinically relevant CD3 population.615
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6nced by the presence of bulky nodular disease
which might have been anticipated to absorb some
f the ATG), and the actual factors that determined
he moderate intersubject variability of this param-
ter were not immediately apparent. The mean
odel parameters were used to simulate the time at
hich ATG levels would decline. For 16 mg/kg
osing, the model predicted that ATG levels would
ecome less than 2 g/mL on day 33 and less than
g/mL on day 49. When the 20 mg/kg dose was
imulated, the equivalent times were 39 days (2
g/mL) and 55 days (1 g/mL). However, the
ntersubject variability of parameters was moderate
the coefﬁcient of variation was approximately
0%), meaning that the precision of this point es-
imate for the population of patients is not likely to
e sufﬁcient to obviate the need for direct measure-
ent of ATG levels.
ISCUSSION
ATG is a commonly used immunosuppressive
gent in allogeneic marrow transplantation that can
ffect the pace of lymphocyte recovery, particularly
fter T cell–depleted transplantations. Until now, en-
yme-linked immunosorbent assays have been used
lmost exclusively to determine serum ATG levels
4,13-15]. We report the development of a 2-color
ow-based assay to quantify active ATG—the ATG
apable of binding to human leukocytes. This method
rovides easy and accurate quantitation of active ATG
n patient serum by using technology that is readily
vailable in any blood or marrow processing labora-
ory.
The assay is technically simple to perform, repro-
ucible, and easy to interpret. Mean (or geometric
ean) log ﬂuorescence intensity of leukocyte binding
emonstrates a linear relationship with ATG concen-
ration. Samples that were run, frozen, and rerun at
A
T
G
 (
µ
g
/m
l)
igure 5. ATG binding to white cell subsets: the disappearance of
ntibody capable of binding to CD3 (T cells), CD13 (myeloid cells),
nd CD56 (NK cells) is illustrated.ater time points typically produced an ATG level that
16ell between the same 2 control points on the standard
urve, although the actual value might vary slightly.
ariation was insufﬁcient to alter either clinical inter-
retations or care. Neat and 1:1 diluted patient serum
ere typically run to demonstrate internal consistency
n each assay; the 1:1 sample produced a concentration
f half or slightly less than half of the neat sample.
During this period, several patients were treated
ith equine ATG. We performed similar assays in
hese patients to determine the level of residual ATG
y using goat anti-horse FITC. There was more non-
peciﬁc binding with the equine product; however, the
ssay also demonstrated a linear relationship between
ean (or geometric mean) log ﬂuorescence intensity
nd equine ATG concentration.
Because T-lymphocytopenia can be quite pro-
onged in recipients of T cell–depleted transplants
ho also receive ATG, our patients commonly receive
LI to boost immune reconstitution. However, we
ere concerned that residual ATG would bind to the
nfused lymphocytes and either contribute to their
emoval or render them functionally ineffective. This
rovided the impetus to explicitly demonstrate that
TG was gone before lymphocyte administration.
We hypothesized that the components of ATG
apable of binding to various leukocyte populations
ight disappear at different rates. ATG is a polyclonal
erum containing antibodies that react broadly with
any leukocyte subpopulations (such as CD45) and
thers that have narrower reactivity (such as CD3 and
D13). We reasoned that the rapid recovery of gran-
locytes, monocytes, and NK cells would likely absorb
nd remove the common and speciﬁc antibodies ca-
able of binding to these subpopulations, whereas the
uch delayed recovery of CD3 lymphocytes would
e associated with more prolonged persistence of an-
ibodies speciﬁc to T cells. The presence of either 2
eaks or tails in the ﬂow cytometry histograms with
-color analysis seemed consistent with antibodies to
ifferent cell subsets disappearing from serum at dif-
erent rates.
To test these hypotheses, we modiﬁed the original
-color assay into a 2-color approach that would allow
able 2. Pharmacokinetic Data
Variable Mean SD
verall half-life (d) 6.8 2.9
lpha half-life (d) 3.0 0.7
eta half-life (d) 17.9 6.6
learance (mL/d) 3405 1716
olume of distribution (L) 47.2 24.9
olume of distribution (mL/kg) 0.594 0.274
f the 30 patients studied, there were not sufﬁcient data points for
6. Pharmacokinetic parameters were calculated for the remain-
ing 24. Of these, 14 followed a biexponential model, and 10
followed a monoexponential model.
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ATG Clearance after HPCT
BTG binding to speciﬁc leukocyte subpopulations to
e assessed. Our primary interest was to address the
isappearance of ATG capable of binding to CD3
ells, because we believed that this would be most
linically relevant. To our surprise, our results indi-
ated that the times to the disappearance of ATG
apable of binding to CD3 cells versus granulocytes
ersus mononuclear cells as a whole were not appre-
iably different.
In reviewing histograms from both groups of pa-
ients (those for whom anti-CD3 PE staining was used
nd those in whom it was not), it is clear that in all
atients there are 2 or more populations of cells that
an be distinguished in the histograms. This can be
een as either 2 separate peaks on the histogram or as
tail leading into or trailing the peak. With the
ddition of anti-CD3 PE, the 2 populations separate
ut more clearly and provide a cleaner and more easily
nterpretable and quantiﬁable result. We have contin-
ed to perform 2-color staining by using goat anti-
abbit FITC and anti-CD3 PE. The same assay can be
asily adapted to look at any other subsets of cells of
nterest or to equine ATG.
Others have studied the pharmacokinetics of ATG
2,8]. In particular, in the HPCT setting, Waller et al.
11] have previously shown that ATG also contains
mmunoglobulins that do not bind to leukocytes, as
ight be expected in any polyclonal serum. We con-
ned our analysis to ATG antibodies capable of bind-
ng to cells or active ATG. Recognizing that nonbind-
ng, or inactive, ATG continues to be present in
atient serum, we nonetheless assumed that the non-
inding ATG is not clinically relevant.
ATG has multiple mechanisms of action, depend-
ng on the concentration in the serum [9]. At higher
evels (10 g/mL), this can include complement-
ependent lysis and apoptosis. At lower levels, anti-
ody-dependent cytotoxicity and other mechanisms
re postulated to be more important. There is limited
nformation to assess at which concentration ATG
ecomes functionally insigniﬁcant. On the basis of the
nalyses of Preville et al. [9], we have targeted a level
f 1 to 2 g/mL. The assay is sufﬁciently sensitive to
etect ATG at levels 1.25 g/mL. Levels 1.25
g/mL were distinguishable in 90% of assays, but
n rare occasions, ﬂuorescence at the lower levels
0.078, 0.156, 0.313, and 0.625 g/mL) could not be
istinguished from background. Indeed, part of our
ationale for initially targeting 1 g/mL as the target
TG level at which to proceed with DLI administra-
ion is that this is the concentration at which cell-
urface staining begins to approximate background
taining. Determining the highest concentration of
esidual ATG that does not interfere with DLI func-
ion will be an important future goal, because by
argeting an ATG level of 2.0 g/mL, as opposed to
.0 g /mL, one can accelerate when DLI can be w
B&MTiven by 2 to 3 weeks in some patients, thereby po-
entially reducing the risk from opportunistic infec-
ions and the related morbidity and mortality.
We determined that there is a variable decline of
abbit ATG among patients. Although the half-life
as 6.8 days in our study, there was a standard devi-
tion of 2.9 days. In some patients, it took several
onths for the ATG to decline to a level we consid-
red optimal for DLI administration. In other pa-
ients, ATG cleared within 4 to 6 weeks after HPCT.
he process of ATG clearance is likely to be due to a
ombination of factors, including both protein degra-
ation and absorption onto the surfaces of lymphohe-
atopoietic cells. The variability among patients most
ikely reﬂects several factors that may be involved in
his phenomenon, including underlying diagnosis, dis-
ase burden at the time of transplantation, age,
eight, concomitant medications, differences in cell
urnover (and, thus, antibody adsorption), and varia-
ions in protein catabolism.
We had hoped to ﬁnd an early marker of time to
isappearance so that we could accurately predict at
hat point a patient would be eligible to receive DLI.
iven a wide range of initial ATG levels, it was con-
eivable that high initial levels would correlate with a
onger time to disappearance. However, this was not
he case. In fact, we were unable to ﬁnd any predictor
f time to disappearance of ATG and found it neces-
ary to follow weekly levels.
The total dose of ATG of 16 to 20 mg/kg used in
ur study is one of the highest reported in the litera-
ure. Doses were originally chosen on the basis of
rior work with equine ATG and a presumed 1:10
abbit-equine potency. It is likely that the prolonged
ime to the disappearance of ATG is related in part to
he high dose, which carries both advantages (less
VHD) and disadvantages (prolonged immune sup-
ression).
ATG pharmacokinetics have been studied primar-
ly in solid organ transplant recipients. In the recent
tudy by Waller et al. [11], rabbit ATG pharmacoki-
etics were studied in HPCT recipients. They de-
cribed 2 phases of clearance of ATG, with an early
lpha clearance during the ﬁrst 4 weeks after trans-
lantation followed by a slower beta clearance during
he subsequent 4 weeks. We also found that ATG
howed a biexponential pattern of elimination, with
alues that were comparable to those seen by Waller
t al. Our model speciﬁed a second compartment
olume of 25 L. This volume, as well as the alpha
alf-life, had a large intersubject variability. Whereas
uch of this early-phase ATG decline in plasma may
e based on distribution out of the central compart-
ent, it may also reﬂect differential binding to target
ells and may be inﬂuenced according to disease type
nd burden. However, no pattern linking these factors
as immediately apparent. Waller and associates used
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6total dose of 6 to 10 mg/kg rabbit ATG and reported
peak level of active ATG of 9.2 g/mL, which is
omewhat lower than our observed initial level of 21.5
g/mL. Given the higher dose of ATG that we ad-
inistered, this is not surprising. Waller’s group re-
orted a t½ of 6 days, which was similar to ours of 8.1
ays (SD, 2.9 days), but with a time to clearance to
ubtherapeutic levels (1 g/mL) of 15 days (range,
-38 days). In our patients, it took much longer for the
TG to disappear to this level, at a median of 47 days
range, 21-83 days), which once again likely reﬂects, at
east in part, the larger dose.
ATGs are commonly used products in both solid
rgan and hematopoietic stem cell transplantation.
ntil now, their use with regard to dose and schedule
as been empiric. The 2-color ﬂow-based assay pre-
ented in this article provides a simple method for
etecting the ATG that is most relevant—the active
TG capable of binding to T lymphocytes. It is ap-
arent from the data presented that the clearance of
TG varies among patients and that there is no pre-
ictor of which patients will clear the drug rapidly and
hich will clear it slowly. It is now feasible to assess
hether rejection of solid organ and hematopoietic
llografts, GVHD, and opportunistic infections cor-
elate with dose, peak serum levels, or rate of decline
f this agent. This should allow use of this agent to
e optimized in the future. For patients receiving
lanned DLI, our current data indicate that one can-
ot rely on peak ATG levels, an empiric date of
dministration, or enzyme-linked immunosorbent as-
ay results to guide therapy, but rather must monitor
erum levels by using this or a similar assay for proper
onclusions regarding dose, safety, and efﬁcacy.
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